TNF and breast carcinoma: Another prospective study showed elevation of the levels of pro-inflammatory markers, free iron (Fe), tumor necrosis factor alpha (TNF-α) and homocysteine were elevated in breast cancer patients treated with doxorubicin (DOX; n = 33), paclitaxel (PTX; n = 35) or trastuzumab (TZ; n = 52) compared to the healthy controls (n = 50).